Ibrexafungerp Citrate CAS No. 1965291-08-0

Uses

Ibrexafungerp citrate is indicated for the treatment of vulvovaginal candidiasis (VVC) in adult and post-menarchal pediatric females. It is also under investigation for the treatment of other systemic fungal infections, including:

• Invasive pulmonary aspergillosis

• Fungal infections (including systemic and invasive candidiasis)

• Pneumocystis infections

• Recurrent vulvovaginal candidiasis

• Coccidioidomycosis

• Histoplasmosis

• Blastomycosis

• Aspergillosis

Dosage and Administration

• Adults and Post-Menarchal Pediatric Females: The recommended dosage is 300 mg (two 150 mg tablets) twice daily for one day, for a total treatment dosage of 600 mg.

• Administration: Ibrexafungerp citrate can be taken with or without food.

Properties and Characteristics

• Molecular Formula: C₅₀H₇₅N₅O₁₁

• Molecular Weight: 922.2 g/mol

• IUPAC Name: (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[(2R)-2-amino-2,3,3-trimethylbutoxy]-1,6a,8,10a-tetramethyl-8-[(2R)-3-methylbutan-2-yl]-14-[5-(pyridine-4-yl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-2H,4H-1,4a-propanophenanthro[1,2-c]pyran-7-carboxylic acid; 2-hydroxypropane-1,2,3-tricarboxylic acid

• InChI: InChI=1S/C44H67N5O4.C6H8O7/c1-27(2)28(3)39(7)18-19-41(9)30-12-13-33-40(8)23-52-25-44(33,31(30)14-17-42(41,10)34(39)37(50)51)22-32(35(40)53-24-43(11,45)38(4,5)6)49-36(47-26-48-49)29-15-20-46-21-16-29;7-3(8)1-6(13,5(11)12)2-4(9)10/h14-16,20-21,26-28,30,32-35H,12-13,17-19,22-25,45H2,1-11H3,(H,50,51);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t28-,30+,32-,33+,34-,35+,39-,40-,41-,42+,43+,44+;/m1./s1

• InChIKey: WKIRTJACGBEXBZ-FQGZCCSZSA-N

• SMILES: CC@H[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)CC@HN6C(=NC=N6)C7=CC=NC=C7)C)C)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

• CAS Number: 1965291-08-0

• UNII: M4NU2SDX3E

• ChEMBL ID: CHEMBL4298168

• KEGG ID: D11545

• NCI Thesaurus Code: C174692

• RXCUI: 2560215

• Wikidata: Q107413412

Important Safety Information

• Pregnancy: Ibrexafungerp citrate is contraindicated in pregnant individuals. Animal studies have shown that it can cause fetal harm.

• Contraception: Females who can become pregnant must use effective contraception during treatment and for at least four days after the last dose.

• Allergic Reactions: Seek immediate medical help if you experience signs of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat; difficulty breathing; or hives.

Side Effects

Common side effects of ibrexafungerp citrate can include:

• Diarrhea

• Nausea

• Vomiting

• Abdominal pain

• Dizziness

• Headache

Mechanism of Action

Ibrexafungerp is a triterpenoid antifungal agent that inhibits β-(1,3)-D-glucan synthase, an essential enzyme in fungal cell wall biosynthesis. This mechanism of action makes it effective against Candida species and other fungi.

Clinical Development

Ibrexafungerp citrate is under clinical development by GSK and is currently in Phase III for Candidiasis. According to GlobalData, Phase III drugs for Candidiasis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Product Documents

• Safety Data Sheet (SDS)
• Certificate of Analysis
• Product Brochure
• Technical Data Sheet